ChemotherapyAdvisor.com Editorial Board member Dr. Barbara Burtness, MD has recommended abstracts that are most significant in terms of clinical impact for the practicing oncologist.
Dr. Burtness is Associate Director and Clinical Research Professor in the Department of Medical Oncology at the Fox Chase Cancer Center in Philadelphia, PA.
Abstract #131
Race and breast cancer prognosis by PAM50 subtype in the LACE and Pathways studies
Candyce Kroenke et al
Continue Reading
Abstract #1137
Expression of specific apoptotic mediators predicts sensitivity to combined MEK and PI3K inhibition in KRAS mutant non-small cell lung cancer according to TP53 mutational status
Aaron Hata et al
Abstract #2343
A novel ERK inhibitor is active in models of acquired resistance to BRAF and MEK inhibitors
Ahmed A. Samatar et al
Abstract #2531
Childhood cancer and traffic-related air pollution exposure in pregnancy and early life
Julia E. Heck et al
Abstract #LB-64
GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study
Dejan Juric et al
Abstract #LB-141
Potent single agent activity of Ibrutinib (PCI-32765) in patients with chronic lymphocytic leukemia (CLL): clinical and translational results from an ongoing phase II study
Adrian Wiestner et al
Abstract #LB144
Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al
Abtract #LB197
First-in-human study with ARQ 092, a novel pan AKT-inhibitor: Results from the advanced solid tumors cohorts
Mansoor Saleh et al
Abstract #LB-289
A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors
Ramesh K. Ramanathan et al
Abstract #LB335
Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer
Lana E. Kandalaft et al
